Literature DB >> 9665276

Potential involvement of IL-8 in the pathogenesis of human cytomegalovirus infection.

T Murayama1, N Mukaida, K S Khabar, K Matsushima.   

Abstract

The observations that several types of viruses induced interleukin (IL)-8 production prompted us to investigate the interrelationship between IL-8 and cytomegalovirus (CMV) infection. CMV infection caused IL-8 production in a human monocytic cell line, THP-1, in dose- and time-dependent manners. Moreover, CMV induced IL-8 gene expression by concurrently activating transcription factors, NF-kappaB and AP-1. Furthermore, CMV infection of human fibroblast cell lines increased gene expression of a specific receptor for IL-8, CXCR1. IL-8 in turn enhanced CMV replication in a human embryonic fibroblast, MRC-5, in dose- and time-dependent manners. Augmented replication eventually culminated in the increased production of infectious CMV virions. Moreover, IL-8 can attenuate the antiviral activity of interferon (IFN), particularly that of alpha-type against picornaviruses such as encephalomyocarditis virus and poliovirus. The inhibitory effects were associated with reduced 2',5'-A oligoadenylate synthetase activity. These results would imply that CMV can induce IL-8, which can augment CMV replication directly and indirectly by counteracting antiviral activity of IFN.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9665276     DOI: 10.1002/jlb.64.1.62

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  8 in total

1.  Lassa and Mopeia virus replication in human monocytes/macrophages and in endothelial cells: different effects on IL-8 and TNF-alpha gene expression.

Authors:  I S Lukashevich; R Maryankova; A S Vladyko; N Nashkevich; S Koleda; M Djavani; D Horejsh; N N Voitenok; M S Salvato
Journal:  J Med Virol       Date:  1999-12       Impact factor: 2.327

2.  Regulation of CXCL-8 (interleukin-8) induction by double-stranded RNA signaling pathways during hepatitis C virus infection.

Authors:  Jessica Wagoner; Michael Austin; Jamison Green; Tadaatsu Imaizumi; Antonella Casola; Allan Brasier; Khalid S A Khabar; Takaji Wakita; Michael Gale; Stephen J Polyak
Journal:  J Virol       Date:  2006-10-11       Impact factor: 5.103

3.  Human gingival CD14(+) fibroblasts primed with gamma interferon increase production of interleukin-8 in response to lipopolysaccharide through up-regulation of membrane CD14 and MyD88 mRNA expression.

Authors:  Riyoko Tamai; Tetsuya Sakuta; Kenji Matsushita; Mitsuo Torii; Osamu Takeuchi; Shizuo Akira; Sachiko Akashi; Terje Espevik; Shunji Sugawara; Haruhiko Takada
Journal:  Infect Immun       Date:  2002-03       Impact factor: 3.441

4.  Specific history of heterologous virus infections determines anti-viral immunity and immunopathology in the lung.

Authors:  Hong D Chen; Armando E Fraire; Isabelle Joris; Raymond M Welsh; Liisa K Selin
Journal:  Am J Pathol       Date:  2003-10       Impact factor: 4.307

5.  Inhibition of inflammatory interleukin-6 activity via extracellular signal-regulated kinase-mitogen-activated protein kinase signaling antagonizes human cytomegalovirus reactivation from dendritic cells.

Authors:  Matthew B Reeves; Teresa Compton
Journal:  J Virol       Date:  2011-09-21       Impact factor: 5.103

6.  Human cytomegalovirus induces TLR4 signaling components in monocytes altering TIRAP, TRAM and downstream interferon-beta and TNF-alpha expression.

Authors:  Kok-Hooi Yew; Cory Carpenter; R Scott Duncan; Christopher J Harrison
Journal:  PLoS One       Date:  2012-09-07       Impact factor: 3.240

7.  The Predictive Value of Interleukin-8 in the Development of Cytomegalovirus Retinitis in HIV-Negative Patients.

Authors:  Zhuyun Qian; Hua Fan; Xu Chen; Yong Tao
Journal:  Ophthalmic Res       Date:  2020-12-16       Impact factor: 3.031

8.  Interleukin 8 activity influences the efficacy of adenoviral oncolytic immunotherapy in cancer patients.

Authors:  Kristian Taipale; Siri Tähtinen; Riikka Havunen; Anniina Koski; Ilkka Liikanen; Päivi Pakarinen; Riitta Koivisto-Korander; Matti Kankainen; Timo Joensuu; Anna Kanerva; Akseli Hemminki
Journal:  Oncotarget       Date:  2018-01-05
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.